Language
- 中文版
- English

Diammonium glycyrrhizinate enteric-coated tablets

Drugs recommended by clinical guidelines of Department of Hepatology

View more →

Combine production, education, research and application

The scientific research level of Anhui Pioneer Shanghai R&D Center is among the top in China

View more →

Pioneer medicated heart system

Pioneer Pharmaceutical Co., Ltd. Professional Focus Concentration

View more →

scroll down

Business scope

Integrating scientific research, production and sales

Pharmaceutical injection

The company makes full use of the advantages of Shanghai R&D talents and information in the key areas of the domestic disease spectrum in the next 20 years

Explore details →

Pharmaceutical Oral Formulations

Developed in cooperation with Lifik Pharmaceuticals, the production approval of the national dosage form of Diamine Glycyrrhizinate Enteric-Coated Tablets was successfully approved

Explore details →

Pharmaceutical agent

Cooperate with many well-known domestic raw material pharmaceutical companies The number of drug research and development approvals ranks among the top among pharmaceutical companies in Anhui Province

Explore details →

2004 year

Established time

2000 Ten thousand

Registered capital

300 +

Number of employees

Anhui Pioneer Pharmaceutical Co., Ltd, founded in Jan 2004, is a pharmaceutical enterprise which engages in pharmaceutical research and development, drug manufacturing, and international trade. It locates in Hefei of China, covering an area of about 20000 square meters .Pioneer has several advanced production lines for injections, capsules, tablets, granules with Chinese GMP certificates. Now the company has six production workshops: one freeze-drying powder for injection workshop

Explore details →

Vision mission

Corporate vision: To be the messenger of human health

Explore details →

Company history

The first stage 2004-2011: the start-up period of enterprises

Explore details →

Company honors

The company has passed a number of related honorary certificates

Explore details →

Team building

The company has more than 300 employees

Explore details →

R & D innovation

Strengthen research and development capabilities

Each year our consultants and experts dedicate themselves to the research and development of several "Management Body of Knowledge"...

Explore details →

Research trends

Strategic consulting is one of the most advantageous consulting services. We have worked on more than 500 strategic projects...

Explore details →

Research strength

The technological level has reached the leading position in the country, achieving an annual production capacity of 30 million bottles, and successfully passed the national...

Explore details →

News Information

Focus on our bit by bit

Warmly welcome the entrepreneurs from the 39th class committee of Cheung Kong Graduate School of Business to visit Pioneer Pharmaceutical

On March 7, 2023, when Goddess Day is approaching, Pioneer Pharmaceuticals welcomes entrepreneur friends from the fourth class committee of the 39th Cheung Kong Graduate School of Business to come to Pioneer to guide the work!

2023

02.27

Warmly congratulate Pioneer Pharmaceutical Clindamycin Phosphate Injection on obtaining the new approval document, new standard and new Ruijia for generic drug registration!

On the occasion of the New Year's Day in 2023 , Anhui Pioneer Pharmaceutical Co., Ltd. received two notices of approval for registration of generic drugs issued by the State Food and Drug Administration. The approved product is Clindamycin Phosphate Injection (Trademark: Xinruijia® ) with specifications of 2ml :0.3g and 4ml:0.6g ), and the approval numbers are Guoyao Zhunzi H20223952 and Guoyao Zhunzi H20223953 respectively . At the beginning of the new year, Pioneer Pharmaceuticals successfully obtained 2 R&D achievements, which will definitely have far-reaching significance for the long-term development of the company!

2023

02.25

Warmly congratulate Anhui Pioneer Pharmaceutical Fenofibrate Capsules for being the first to pass the consistency evaluation of generic drugs

On February 24, 2023, Anhui Pioneer Pharmaceutical Co., Ltd. (hereinafter referred to as "Pioneer Pharmaceutical") ushered in the approval and issuance of the approval document for the consistency evaluation of generic drugs this year. The State Drug Administration approved and issued the "Drug Supplementary Application Approval Document", officially notifying Anhui Pioneer Pharmaceuticals that "Fenofibrate Capsules" is the first to pass the consistency evaluation of generic drug quality and efficacy!

2020

09.24

Cooperation in the field of big health

On Wednesday, September 23, 2020, cooperative customers in the field of general health visited Pioneer, accompanied by Chairman Chen Dong, Vice President of Sales He Chuanlan, Sales Director Gao Lixia, Marketing Director Li Xiaobao, etc. Customers have fully recognized Pioneer's product technology and quality standard system, as well as the after-sales system. In the later stage, we will explore new models together and strengthen cooperation.